Clinical Core

临床核心

• 批准号: 10461182
• 负责人: Jeff Douglas Williamson
• 金额: $ 77.9万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10461182
• 关键词: Address; Adult; Aging; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Biological Markers; Biometry; Blood Vessels; Brain; COVID-19 pandemic; Classification; Clinical; Clinical Research; Cognitive; Cohort Studies; Consensus; Consultations; Data; Dementia; Development; Disease; Elderly; Enrollment; Ensure; Evaluation; Faculty; Fostering; Foundations; Glucose Intolerance; Growth; Hypertension; Image; Liquid substance; Magnetic Resonance Imaging; Measures; Metabolic; Mitochondria; Monitor; Multicenter Trials; Nerve Degeneration; Participant; Pathway interactions; Patient Recruitments; Persons; Physical activity; Positron-Emission Tomography; Prevalence; Prevention strategy; Publications; Registries; Research; Research Personnel; Resources; Risk; Role; Sampling; Services; Sleep; Spinal Puncture; Telephone; Underrepresented Populations; Validation; Vascular Dementia; Work; arterial stiffness; cerebrovascular; clinical database; cohort; data exchange; data management; education research; forest; glucose metabolism; glucose tolerance; health disparity; heart rate variability; high standard; imaging biomarker; innovation; interest; lifestyle factors; neuroimaging; neuropathology; normal aging; operation; outreach; participant retention; precision medicine; programs; recruit; relational database; resilience; success; symposium; tau Proteins; tool; vascular factor

Clinical Core – Project Summary The Clinical Core (CC) is the centerpiece of the Wake Forest Alzheimer’s Disease Research Center (WF ADRC), providing rigorously collected and innovative resources to advance the ADRC themes: to elucidate the factors influencing the transitions from normal aging to MCI and dementia, with special emphasis on understanding the role of vascular and metabolic conditions and health disparities in these transitions. Although in existence for only four years, the CC has surpassed its original enrollment target of 500 participants. As of August 2020, we enrolled 583 participants (20% from underrepresented groups), contributed 1135 UDS3 evaluations and 555 MRI images to NACC, and 295 samples to NCRAD. The CC has also contributed 256 well-characterized participants to clinical studies. Consonant with the WF ADRC focus on early transitions, the cohort is weighted toward cognitively normal adults and participants with MCI, with a smaller number of participants with AD, mixed AD/vascular or other dementias. All participants have been carefully characterized with the UDS3 and MRI, and with specialized metabolic and vascular measures. Many participants have also undergone lumbar puncture, amyloid or tau PET, and mitochondrial analysis. In the coming cycle, we will increase the CC cohort size to follow 600 participants and will introduce a panel of innovative biometric measures relating to sleep, physical activity, glucose metabolism, and vascular function. The CC cohort is well-suited to address WF ADRC themes and provide resources that will contribute to greater understanding of the influence of metabolic/vascular factors and health disparities on ADRD risk. Approximately 70% of CC participants have glucose intolerance or hypertension, as expected given high regional prevalence of these disorders. To facilitate research on the role of health disparities in AD risk, we will work with the Outreach, Recruitment and Engagement Core to maximize engagement with underrepresented groups. Our CC will also align with the WF Older Adults Independence Center (OAIC) to facilitate studies on the role of aging in AD. Further, CC investigators will participate in an innovative program to foster alignment of large cohort studies with ADRC practices through the Clinical HArmonization and IMPlementation Service (CHAMPS). WF CHAMPS led the development and piloting of the UDS3 Telephone/Video Cognitive Battery provided to ADRCs when in-person research was restricted due to the COVID-19 pandemic. In summary, our CC has made exceptional progress in its first 4 years; it has enrolled 583 participants, contributed copious resources to the ADRC network, and provided a foundation for the explosive growth of ADRD research at Wake Forest. In the next cycle, we will leverage this success to further promote high-impact research on strategies for prevention and treatment of AD and related disorders.

临床核心-项目总结 临床核心（CC）是维克森林阿尔茨海默病研究中心的核心 (WF ADRC），提供严格收集和创新的资源，以推进ADRC的主题： 阐明影响从正常衰老到MCI和痴呆的转变的因素，特别是 强调了解血管和代谢条件的作用和健康差异， 这些过渡。虽然存在只有四年，CC已经超过了它原来的招生 目标500人。截至2020年8月，我们招募了583名参与者（20%来自代表性不足 组），向NACC提供了1135个UDS 3评价和555个MRI图像，向NCRAD提供了295个样本。的 CC还为临床研究贡献了256名具有良好特征的参与者。与WF ADRC一致 关注早期过渡，该队列侧重于认知正常的成年人和MCI参与者， AD、AD/血管性痴呆或其他痴呆的参与者数量较少。所有参与者都 使用UDS 3和MRI以及专门的代谢和血管测量仔细表征。 许多参与者还接受了腰椎穿刺、淀粉样蛋白或tau PET和线粒体分析。在 在下一个周期，我们将增加CC队列的规模，以跟踪600名参与者，并将引入一个小组， 与睡眠、身体活动、葡萄糖代谢和血管功能相关的创新生物计量。 CC队列非常适合解决WF ADRC主题，并提供资源， 有助于更好地了解代谢/血管因素和健康的影响 ADRD风险的差异。大约70%的CC参与者患有葡萄糖耐受不良或高血压， 鉴于这些疾病的高区域流行率，这是预期的。促进关于健康作用的研究 广告风险的差异，我们将与外展，招聘和参与核心，以最大限度地提高 与代表性不足的群体接触。我们的CC也将与WF老年人独立 中心（OAIC），以促进对老龄化在AD中的作用的研究。此外，CC研究人员将参加一个 创新计划，通过临床研究促进大型队列研究与ADRC实践的一致性 协调和执行服务（CHAMPS）WF CHAMPS领导了 当面对面研究因以下原因而受到限制时，向ADRC提供UDS 3电话/视频认知成套测验 COVID-19大流行。总而言之，我们的CC在最初的4年里取得了非凡的进步;它 招募了583名参与者，为ADRC网络提供了丰富的资源，并为 维克森林ADRD研究的爆炸性增长。在下一个周期，我们将利用这一成功， 进一步促进对预防和治疗AD及相关疾病的策略的高影响力研究。